Oral Vaccines Market Driven by Rising Awareness, Government Participation, says TMR

Transparency Market Research (TMR) announces a new report on the global oral vaccines market. The report provides readers with thorough forecasts regarding various aspects of the global oral vaccines market based on solid analysis of the market’s present and historical figures. The report examines the segmentation of the global oral vaccines market in order to present a granular picture of the market, while profiles of leading players in the oral vaccines market help present a clear picture of the competitive dynamics of the market. The report is titled ‘Oral Vaccines Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025.’

Oral vaccines have replaced conventional parenteral vaccines in several applications due to their greater comfort to the user due to the absence of needles. The inconvenience associated with needles is the key driver for the global oral vaccines market. The safety of oral vaccines has become a key factor for patient demographics and is likely to remain an important driver for the global oral vaccines market in the coming years.

By disease, the global oral vaccines market is segmented into HIV, influenza, rabies, polio, cholera, rotavirus, and others. Of these, HIV and influenza vaccines are likely to be the key product segments of the global oral vaccines market in the coming years due to the growing prevalence of HIV in developing regions and the annual risk of influenza outbreaks. Tuberculosis vaccines are also likely to remain an important segment of the global oral vaccines market, mainly due to the rising prevalence of the disease in underdeveloped regions such as Africa.

By vaccine type, the global oral vaccines market is segmented into attenuated, inactive, recombinant, and other vaccines. Of these, inactive vaccines are likely to remain the key revenue generator for the global oral vaccines market due to them being safer than live (attenuated) vaccines. The rising adoption of inactive vaccines in national immunization programs, due to their promising cost-effectiveness, is thus likely to remain a key driver for the global oral vaccines market in the coming years.

Accordingly, government vaccination programs accounted for a dominant share in the global oral vaccines market and are likely to continue as a major revenue generator for the market. Clinics are also a dominant end user segment of the global oral vaccines market and are likely to benefit from the increasing number of users with high awareness about the importance of vaccination.

North America is the regional leader in the global oral vaccines market due to the high disposable income of citizens in the region. The rising opposition to the use of needles in vaccines is likely to drive the North America oral vaccines market in the coming years. Steady government involvement in immunization drives in countries such as the U.S. and Canada is also vital for the North America oral vaccines market. However, the growing anti-vaccine movement in the U.S. could hamper the oral vaccines market’s growth in North America in the coming years.

Leading players in the global oral vaccines market include GlaxoSmithKline Plc, Aventis, Serum Institute of India Pvt. Ltd., Swiss Serum and Vaccine Institute Berne, PaxVax Corporation, Merck & Co. Inc., Janssen Pharmaceuticals, VALNEVA Canada Inc., and Shanghai BravoBio Co. Ltd.

Request to View Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=24041